Leidi.com Lei Jianping April 6
Sanbo Brain Hospital Management Group Co., Ltd. (abbreviation: "Sanbo Brain") has recently passed registration and is preparing to be listed on the GEM of the Shenzhen Stock Exchange.
Sanbo Brain Science plans to raise 500 million yuan, of which 300 million yuan will be used for the Hunan Sanbo Brain Hospital project, 70.1 million yuan will be used for the Sanbo Brain Science information construction project, and 130 million yuan will be used to supplement working capital.
Annual revenue 1.137 billion
Sanbo Brain Medicine was founded in 2003 by neuromedical experts Luan Guoming, Yu Chunjiang, Shi Xiangen, and senior medical management expert Zhang Yang. They explored a new hospital management model and formed a medical investment, hospital management, and brand operation. It is a medical group that integrates "medical treatment, teaching and scientific research".
Sanbo Brain Science takes neurology as the leader, strengthens the development model of specialties and small comprehensive, and forms a medical service network covering the core areas of the country. The service diseases cover various neurological diseases such as brain tumors, cerebrovascular, functional neurosurgery, spinal cord, and pediatric brain and brain diseases, as well as gynecology, pediatrics, internal medicine, surgery, pain, general medicine and other diseases.
According to the prospectus, Sanbo Brain's revenue in 2019, 2020, and 2021 will be 1.019 billion yuan, 987 million yuan, and 1.137 billion yuan respectively; net profits will be 54.9269 million yuan, 74.079 million yuan, and 87.3778 million yuan; The net profits were 73.09 million yuan, 67.7128 million yuan, and 74.3596 million yuan, respectively.
In the first half of 2022, Sanbo Brain's revenue was 532 million yuan, its net profit was 40.458 million yuan, and its net profit after deducting non-existing expenses was 29.709 million yuan.
TBP and Taikang Life are shareholders
The controlling shareholders and actual controllers of Sanbo Brain are Zhang Yang, Luan Guoming, Yu Chunjiang and Shi Xiangen. The above-mentioned shareholders exercise joint control over the company through the "Action in Concert Agreement", holding a total of 34.6472 million shares, with a shareholding ratio of 29.15%.
Before the IPO, Zhang Yang held 14.12% of the shares, Yu Chunjiang and Luan Guoming each held 5.56%, Shi Xiangen held 3.91%, TBP held 20.93%, Taikang Life Insurance held 6.31%, and Lin Ruiyan held 4.28% %, Ningbo Investment and Kaitai Borui hold 3.94% of the shares respectively, Xinde Longyan holds 3.08% of the shares, Yang Hongpeng holds 3.07% of the shares, and Bokang Hengtai holds 2.76% of the shares;
Bochuang Shengxiang holds 2.72%, Vaucluse Capital holds 2.31%, Yingtan Investment holds 2.13%, Yingxinda Investment holds 1.98%, Boda Xincheng holds 1.81%, Boren Yutai holds is 1.58%, and Yikai Fund holds 1.26%.
Zhang Yang, born in October 1965, graduated from Beijing Institute of Technology with a bachelor's degree in 1988; in 1999, graduated from Beijing Institute of Technology with a master's degree; in 2007, graduated from Guanghua School of Management, Peking University with an executive master's degree in business administration. From 1988 to 1992, worked in Beijing Camera General Factory and Beijing Haidian Beike Instrument Factory; from 1992 to 2004, served as the chairman and general manager of Beijing Beike Digital Medical Technology Co., Ltd.; from 2004 to 2014, served as General Manager of Sanbo Brain Science; since 2014, he has served as Chairman and General Manager of Sanbo Brain Science.
Luan Guoming, born in September 1959, has permanent residency in the United States. In 1992, he graduated from Beijing Tiantan Hospital affiliated to Capital Medical University and Beijing Institute of Neurosurgery (Beijing) with a doctorate in neurosurgery. From 1982 to 1986, resident doctor in surgery and neurosurgery at the Affiliated Hospital of Jiamusi Medical College; from 1987 to 1989, attending doctor and lecturer in neurosurgery in the First Affiliated Hospital of China Medical University; from 1989 to 1992, attending doctor in neurosurgery in Beijing Tiantan Hospital Teacher; from 1992 to 1994, assistant researcher and postdoctoral fellow in neurosurgery, University of California, Los Angeles School of Medicine; from 1994 to 1998, deputy director of neurosurgery and functional neurosurgery, Beijing Tiantan Hospital, associate professor, master supervisor, Beijing Neurology Director of the Department of Neurobiology, Institute of Surgery;
From 1998 to 2002, Luan Guoming served as the Chief Physician, Professor and Doctoral Supervisor of Neurosurgery and Functional Neurosurgery of Beijing Tiantan Hospital; from 2003 to 2004, he served as the Chief Physician, Professor and Doctoral Supervisor of Neurosurgery of Beijing Hospital of the Ministry of Health. Director of the Biochemical Blood Lipid Department of the Institute of Geriatric Diseases of the Ministry of Health; since 2004, he has served as director of Sanbo Brain Hospital, professor, doctoral supervisor, chief physician, chief expert of Sanbo Brain Hospital of Capital Medical University, and director of the third department of the College of Surgery, Capital Medical University.
Yu Chunjiang, born in December 1955, graduated from Capital Medical University with a doctorate in neurosurgery in 1992. From 1988 to 2004, he successively served as attending physician, deputy chief physician, chief physician, associate professor, professor, administrative deputy director of Beijing Tiantan Hospital Affiliated to Capital Medical University, director of neuroanatomy laboratory of Beijing Institute of Neurosurgery, among them, from 1993 to 1995 In 2004, he was a postdoctoral fellow in neurosurgery at the University of Florida School of Medicine; since 2004, he has served as a director of Sanbo Brain Hospital, a professor, doctoral supervisor, chief physician, and chief expert at Sanbo Brain Hospital of Capital Medical University.
After the IPO, Zhang Yang held 10.59%, Yu Chunjiang and Luan Guoming each held 4.17%, Shi Xiangen held 2.93%, TBP held 15.7%, Taikang Life Insurance held 4.74%, and Lin Ruiyan held 3.21% %, Ningbo Investment and Kaitai Borui hold 2.95% of the shares respectively, Xinde Longyan holds 2.31% of the shares, Yang Hongpeng holds 2.3% of the shares, and Bokang Hengtai holds 2.07% of the shares;
Bochuang Shengxiang holds 2.04%, Vaucluse Capital holds 1.74%, Yingtan Investment holds 1.6%, Yingxinda Investment holds 1.48%, Boda Xincheng holds 1.36%, Boren Yutai holds is 1.18%, and Yikai Fund holds 0.95%.
———————————————
Lei Di was founded by Lei Jianping, a media person. If you reprint, please indicate the source.
